While social media influencers like Instagram and YouTube stars can receive big bucks, for the vast majority of creators, a new model was needed to connect directly with a paying audience. Platforms like Patreon free idea makers from reliance on the internet s trillion-dollar gatekeepers like YouTube parent Alphabet and Instagram parent Facebook, which keep most of the advertising-generated revenue. A lot of the distribution platforms are starting to wake up to this and see that creators have a lot of earnings potential, Conte said. All the distribution platforms whether it s Spotify or YouTube or Twitter or Facebook they re all creating ways for creators to earn subscription revenue from their fans.
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NeoGenomics, Inc.: NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million
Completes $200 million strategic financing with leading oncology-focused specialist investors
FT. MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acquire Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England. The acquisition follows a $25 million minority equity investment by NeoGenomics in Inivata in May 2020, at which time NeoGenomics was granted a fixed price option to purchase the remainder of Inivata for $390 million prior to December 31, 2021. The cash purchase price will be funded with balance sheet cash and through
Was The Smart Money Right About Humana Inc (HUM)? yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affinia Therapeutics Closes $110 Million Series B Financing
Affinia TherapeuticsMay 3, 2021 GMT Financing co-led by EcoR1 Capital and Farallon Capital Management
Proceeds to support continued development of proprietary platform for rationally designed adeno-associated virus vectors (AAV) and advance programs into the clinic
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced it has closed an oversubscribed $110 million Series B financing with a premier syndicate of life science investors, co-led by EcoR1 Capital and Farallon Capital Management. Additional new investors participating in the round include Avidity Partners, Casdin Capital, GV (formerly Google Ventures), Octagon Cap